Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Withdrawn

    Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

    Reason given in the registry

    “Change in Study Design”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Ossium Health, Inc.
    Registry record
    NCT05170828
  2. Terminated

    Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2026.

    Ended
    Oct 2025
    Phase
    Phase 1
    Run by
    Brian Jonas
    Registry record
    NCT04964505
  3. Terminated

    A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

    Reason given in the registry

    “The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    Hutchmed
    Registry record
    NCT04764474
  4. Terminated

    A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

    Reason given in the registry

    “As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Jan 2026.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    NextCure, Inc.
    Registry record
    NCT05787496
  5. Terminated

    Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

    Reason given in the registry

    “The data met the protocol-specified criteria for futility of the investigational treatment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2026.

    Ended
    Jan 2026
    Phase
    Phase 3
    Run by
    Delta-Fly Pharma, Inc.
    Registry record
    NCT03926624
  6. Terminated

    A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

    Reason given in the registry

    “Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.

    Ended
    Oct 2024
    Phase
    Phase 2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04150029
  7. Terminated

    Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

    Reason given in the registry

    “Study was terminated early due to lack of accrual and loss of funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.

    Ended
    Sept 2024
    Phase
    Phase 2
    Run by
    Sanjay Mohan
    Registry record
    NCT05799079
  8. Terminated

    Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

    Reason given in the registry

    “business/strategic reason”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2025.

    Ended
    Aug 2025
    Phase
    Phase 1/2
    Run by
    JW Pharmaceutical
    Registry record
    NCT03055286
  9. Terminated

    Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

    Reason given in the registry

    “The research center has conducted a more comprehensive study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2025.

    Ended
    Jan 2024
    Phase
    Phase 2
    Run by
    Institute of Hematology & Blood Diseases Hospital, China
    Registry record
    NCT05361057
  10. Terminated

    Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

    Reason given in the registry

    “Drug company withdrew support.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Dec 2025.

    Ended
    Mar 2025
    Phase
    Phase 1/2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT05918055
  11. Suspended

    A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Product manufacturing process improvement”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2025.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    He Huang
    Registry record
    NCT06709131
  12. Terminated

    A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

    Reason given in the registry

    “Slow enrolment”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2025.

    Ended
    Oct 2025
    Phase
    Phase 1
    Run by
    Kahr Medical
    Registry record
    NCT04937166
  13. Terminated

    Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

    Reason given in the registry

    “The study terminated early because the company was longer providing the investigational product.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2025.

    Ended
    Sept 2024
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04874194
  14. Terminated

    Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

    Reason given in the registry

    “Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Marker Therapeutics, Inc.
    Registry record
    NCT04511130
  15. Terminated

    Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

    Reason given in the registry

    “Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04623216
  16. Terminated

    CD123 Redirected T Cells for AML in Pediatric Subjects

    Reason given in the registry

    “Administrative reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.

    Ended
    May 2025
    Phase
    Phase 1
    Run by
    University of Pennsylvania
    Registry record
    NCT04678336
  17. Terminated

    VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

    Reason given in the registry

    “Business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.

    Ended
    Jul 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04702425
  18. Terminated

    HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT03940352
  19. Terminated

    ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

    Reason given in the registry

    “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.

    Ended
    Jul 2025
    Phase
    Phase 2
    Run by
    TC Biopharm
    Registry record
    NCT05358808
  20. Terminated

    Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

    Reason given in the registry

    “Lack of Funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    Vor Biopharma
    Registry record
    NCT04849910
  21. Terminated

    Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

    Reason given in the registry

    “Lack of Funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    Vor Biopharma
    Registry record
    NCT05984199
  22. Terminated

    A Long-term Follow-up Study of Patients Who Received VOR33

    Reason given in the registry

    “Lack of Funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.

    Ended
    May 2025
    Run by
    Vor Biopharma
    Registry record
    NCT05309733
  23. Withdrawn

    TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

    Reason given in the registry

    “No funding available.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.

    Run by
    Neena Kapoor, M.D.
    Registry record
    NCT05968170
  24. Terminated

    AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “sponsor decision, unrelated to safety”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2025.

    Ended
    May 2024
    Phase
    Phase 1
    Run by
    Amgen
    Registry record
    NCT02675452
  25. Terminated

    Connect® Myeloid Disease Registry

    Reason given in the registry

    “Business objectives have changed”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.

    Ended
    Oct 2024
    Run by
    Celgene
    Registry record
    NCT01688011
  26. Terminated

    Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

    Reason given in the registry

    “In light of the strategic realignment of the company's development focus, it has been determined to discontinue the further development of Uproleselan Injection.”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.

    Ended
    Aug 2024
    Phase
    Phase 3
    Run by
    Apollomics Inc.
    Registry record
    NCT05054543
  27. Terminated

    CART-38 in Adult AML and MM Patients

    Reason given in the registry

    “Administrative decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Jun 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    University of Pennsylvania
    Registry record
    NCT05442580
  28. Withdrawn

    A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

    Reason given in the registry

    “Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Jun 2025.

    Phase
    Phase 1
    Run by
    Janssen Research & Development, LLC
    Registry record
    NCT05521087
  29. Terminated

    A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

    Reason given in the registry

    “Trial terminated because of lack of efficacy in the short term acute phase.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2025.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Celgene
    Registry record
    NCT02848001
  30. Withdrawn

    Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

    Reason given in the registry

    “no patients”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Beijing Boren Hospital
    Registry record
    NCT05248685

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.